Topics

Teva Announces Launch of a Generic Version of Letairis® (ambrisentan) Tablets in the United States

15:01 EDT 1 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Letairis®1 (ambrisentan) Tablets, 5 mg and 10 mg, in the U.S. Ambrisentan is an endothelin receptor antagoni...

Other Sources for this Article

IR Contacts
United States
Kevin C. Mannix
(215) 591-8912
Ran Meir
972 (3) 926-7516

PR Contacts
United States
Kelley Dougherty
(973) 658-0237
Israel
Yonatan Beker
972 (54) 888 5898

NEXT ARTICLE

More From BioPortfolio on "Teva Announces Launch of a Generic Version of Letairis® (ambrisentan) Tablets in the United States"

Quick Search

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Generics Drugs
A generic drug (generic drugs, short: generics) is a drug defined as "a drug product that is comparable to brand/reference listed drug product in dosage form, strength, route of administration, quality and performance characteristics, and intended u...